Senzime receives a new order from South Korea on systems and disposable sensors to a value of more than 1 MSEK


 

This is the fifth larger order placed by Senzimes distributor in South Korea since their market launch in August 2019. There are more than 3,000 hospitals in South Korea and more than 700 000 operations are performed annually where anesthesia and muscle relaxants are used. The company also expects that South Korea's state reimbursement system will include this type of disposable sensors in 2021.

Pia Renaudin, CEO of Senzime states, "TetraGraph's area of ​​application is wide as the product can be used at all times when muscle relaxants are given, regardless of whether it takes place in an operating room or intensive care unit. Our flexible solution with both electricity and battery operation allows the system to accompany the patient to the postoperative ward, something that is much appreciated in South Korea”.

TetraGraph is a unique digital system that measures the presence and depth of neuromuscular blockade to enable the doctor to determine the correct drug dosage and assess when the patient is ready to breathe on their own without the risk of complications. In addition to South Korea, Senzime has launched sales of TetraGraph in Japan, Australia, Europe and the United States.

For further information, please contact: 

Pia Renaudin, CEO of Senzime AB                                                   

Tel: +46 (0)70-813 34 17, email: pia.renaudin@senzime.com   

TO THE EDITORS

About Senzime

Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq
First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399,
info@fnca.se is Certified Adviser for Senzime. www.senzime.com

This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on November 25, 2020, 13:00.